Deal includes option to purchase remaining 40% of dermocosmetics brand within three years.
Eurofarma announced on Monday (17) the acquisition of a 60% majority stake in Klibra Agenciamento de Marcas e Negócios, the owner of dermocosmetics brand Dermage, for R$156 million ($27,4 million).
The agreement also includes an option to acquire the remaining 40% of the company within three years after the transaction’s completion, which is still subject to approval by the Administrative Council for Economic Defense (CADE).
People familiar with the matter said the pharmaceutical company controlled by businessman Maurizio Billi—one of the largest in the industry and domestically owned—plans to use Dermage as a platform to expand in the rapidly growing skincare segment in Brazil. Ilana Braun, daughter of the brand’s founder, will remain at the helm of the company.
One source said Eurofarma’s ambition is to build a strong player in this niche capable of competing with Hypera, which owns Mantecorp—a brand behind product lines such as Episol (sunscreen) and Ivy C (anti-aging).
Eurofarma had already made a move in this segment last year with the acquisition of Medimetriks Pharmaceuticals, marking its entry into the U.S. market. In 2023, the company also launched OAZ, a brand focused on personal care and hygiene, initially introducing 16 products in May, including sunscreens.
Discussions between Eurofarma and Dermage began about a year ago and were initiated directly between the two parties, sources said. However, other companies, including O Boticário and Aché, also considered acquiring the brand.
In a statement about the transaction, Eurofarma highlighted that Dermage, founded in 1978, is recognized for developing high-quality, effective products, strengthening its portfolio in segments with significant growth potential. Dermage currently operates more than 70 stores across Brazil and offers a portfolio of over 200 products, which are also sold through pharmaceutical retail channels.
Source: Valor International
